Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) EBT (2018 - 2025)

Bicycle Therapeutics' EBT history spans 8 years, with the latest figure at $206.6 million for Q4 2025.

  • For Q4 2025, EBT rose 63.07% year-over-year to $206.6 million; the TTM value through Dec 2025 reached $6.6 million, up 14.34%, while the annual FY2025 figure was $6.6 million, 14.34% up from the prior year.
  • EBT reached $206.6 million in Q4 2025 per BCYC's latest filing, up from -$58.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $206.6 million in Q4 2025 to a low of -$79.2 million in Q2 2025.
  • Average EBT over 5 years is -$17.5 million, with a median of -$29.5 million recorded in 2022.
  • Peak YoY movement for EBT: soared 359.69% in 2024, then crashed 129.78% in 2025.
  • A 5-year view of EBT shows it stood at -$18.8 million in 2021, then crashed by 61.82% to -$30.4 million in 2022, then plummeted by 60.47% to -$48.8 million in 2023, then skyrocketed by 359.69% to $126.7 million in 2024, then soared by 63.07% to $206.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's EBT are $206.6 million (Q4 2025), -$58.9 million (Q3 2025), and -$79.2 million (Q2 2025).